Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Dolin

Showing results (91-100 of 101) with videos related to

Pageof 11
Sort By:
The Journal of Infectious Diseases|October 1, 1994
Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials NetworkB S Graham, G J Gorse, D H Schwartz, et al.
Antiviral Therapy|May 1, 2001
Meta-analysis of five randomized controlled trials comparing continuation of zidovudine versus switching to didanosine in HIV-infected individualsJ M Raboud, J S Montaner, S Rae, et al.
The American Journal of Medicine|July 20, 1982
Controlled trial of oral acyclovir in the therapy of recurrent herpes simplex genitalis. A preliminary reportR C Reichman, M Ginsberg, E Barrett-Connor, et al.
Studies in Health Technology and Informatics|October 18, 2001
Kaiser Permanente's "metadata-driven" national clinical intranetR H Dolin, M Boles, R Dolin, et al.
AIDS Research and Human Retroviruses|May 20, 1996
Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation GroupM C Keefer, B S Graham, M J McElrath, et al.
The Journal of Infectious Diseases|February 1, 1996
A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation GroupG J Gorse, M C Keefer, R B Belshe, et al.
AIDS Research and Human Retroviruses|June 30, 2000
A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation GroupM J McElrath, L Corey, D Montefiori, et al.
The Journal of Infectious Diseases|February 1, 1996
Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation GroupJ R Mascola, S W Snyder, O S Weislow, et al.
The Journal of Infectious Diseases|October 1, 1996
Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 TeamS L Welles, J B Jackson, B Yen-Lieberman, et al.
The Journal of Infectious Diseases|February 18, 1998
Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection GroupB S Graham, M J McElrath, R I Connor, et al.
Pageof 11

Showing results (91-100 of 101) with videos related to

Sort By:
Pageof 11
The Journal of Infectious Diseases|October 1, 1994
Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials NetworkB S Graham, G J Gorse, D H Schwartz, et al.
Antiviral Therapy|May 1, 2001
Meta-analysis of five randomized controlled trials comparing continuation of zidovudine versus switching to didanosine in HIV-infected individualsJ M Raboud, J S Montaner, S Rae, et al.
The American Journal of Medicine|July 20, 1982
Controlled trial of oral acyclovir in the therapy of recurrent herpes simplex genitalis. A preliminary reportR C Reichman, M Ginsberg, E Barrett-Connor, et al.
Studies in Health Technology and Informatics|October 18, 2001
Kaiser Permanente's "metadata-driven" national clinical intranetR H Dolin, M Boles, R Dolin, et al.
AIDS Research and Human Retroviruses|May 20, 1996
Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation GroupM C Keefer, B S Graham, M J McElrath, et al.
The Journal of Infectious Diseases|February 1, 1996
A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation GroupG J Gorse, M C Keefer, R B Belshe, et al.
AIDS Research and Human Retroviruses|June 30, 2000
A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation GroupM J McElrath, L Corey, D Montefiori, et al.
The Journal of Infectious Diseases|February 1, 1996
Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation GroupJ R Mascola, S W Snyder, O S Weislow, et al.
The Journal of Infectious Diseases|October 1, 1996
Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 TeamS L Welles, J B Jackson, B Yen-Lieberman, et al.
The Journal of Infectious Diseases|February 18, 1998
Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection GroupB S Graham, M J McElrath, R I Connor, et al.
Pageof 11